OraSure Technologies Reports 32% Revenue Decline and Increased Losses in Q3 2025

OraSure Technologies, Inc. reported a significant decline in financial performance for the third quarter and the first nine months of 2025, as detailed in its latest 10-Q filing. For the three months ended September 30, 2025, the company generated net revenues of $27.1 million, a decrease of 32% from $39.9 million in the same period of 2024. The nine-month figures showed a similar trend, with revenues falling 41% to $88.3 million from $148.4 million year-over-year. The company recorded a net loss of $13.7 million for the third quarter, compared to a loss of $4.5 million in the prior year, and a cumulative loss of $49.4 million for the nine months, up from $8.7 million in 2024.

The decline in revenues was attributed to several factors, including reduced international HIV revenues due to decreased funding and customer ordering patterns, as well as a significant drop in COVID-19 diagnostics sales, which fell 96% to $0.09 million from $2.2 million. The company also discontinued its risk assessment product line, which had contributed $1.9 million in revenue during the same quarter in 2024. In contrast, non-product and services revenues increased significantly, rising 565% to $1.7 million, primarily due to funded research and development contracts acquired through the company's acquisition of Sherlock Biosciences.

In terms of operational changes, OraSure has been actively restructuring its workforce and operations. The company executed a reduction in workforce in 2024, which has led to decreased sales and marketing expenses, down 17% to $6.3 million for the third quarter. Research and development expenses, however, increased by 80% to $10.1 million, driven by higher spending on clinical trials related to new diagnostic devices. The company also reported a change in the estimated fair value of acquisition-related contingent consideration, which contributed to the overall operating loss of $16.1 million for the quarter.

On the balance sheet, OraSure's total assets decreased to $423.1 million as of September 30, 2025, down from $479.7 million at the end of 2024. Cash and cash equivalents also fell to $216.5 million, a decline of $51.3 million from the previous year. The company’s working capital decreased to $242.8 million, reflecting the impact of lower sales and operational adjustments. The company has initiated a stock repurchase program, authorizing the buyback of up to $40 million in shares, with $10 million already spent in the first nine months of 2025.

Looking ahead, OraSure's management remains cautious about the future, particularly regarding the ongoing impacts of reduced funding for HIV programs and the overall demand for COVID-19 testing. The company is also preparing for the integration of BioMedomics, Inc., which it plans to acquire in the fourth quarter of 2025, a move that could potentially enhance its product offerings and market position. However, the company acknowledges that its financial performance may continue to be affected by external market conditions and internal restructuring efforts.